Cargando…

Can Systemic Anti-CD20 B Cell-Depleting Antibodies Eliminate Meningeal Follicles in Multiple Sclerosis?

Detalles Bibliográficos
Autores principales:	Gupta, Sasha, Zamvil, Scott S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130009/ https://www.ncbi.nlm.nih.gov/pubmed/34001659 http://dx.doi.org/10.1212/NXI.0000000000001000

Ejemplares similares

Anti-CD20 therapy depletes activated myelin-specific CD8(+) T cells in multiple sclerosis
por: Sabatino, Joseph J., et al.
Publicado: (2019)

Anti-CD20 Depletes Meningeal B Cells but Does Not Halt the Formation of Meningeal Ectopic Lymphoid Tissue
por: Brand, Rosa Margareta, et al.
Publicado: (2021)

Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity
por: Lehmann-Horn, Klaus, et al.
Publicado: (2014)

Ocrelizumab Depletes CD20(+) T Cells in Multiple Sclerosis Patients
por: Gingele, Stefan, et al.
Publicado: (2018)

Depletion of CD200+ Hair Follicle Stem Cells in Human Prematurely Gray Hair Follicles
por: Mohanty, Sujata, et al.
Publicado: (2013)

Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple Sclerosis
por: Roodselaar, Jay, et al.
Publicado: (2021)

B cells reappear less mature and more activated after their anti-CD20–mediated depletion in multiple sclerosis
por: Nissimov, Nitzan, et al.
Publicado: (2020)

B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies
por: Leandro, Maria J
Publicado: (2013)

Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
por: Saidha, Shiv, et al.
Publicado: (2023)

Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy
por: Freeman, Sean A., et al.
Publicado: (2023)

Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody
por: Rouzière, Anne-Sophie, et al.
Publicado: (2005)

Effect of Subcutaneous Anti-CD20 Antibody-Mediated B Cell Depletion on Susceptibility to Pneumocystis Infection in Mice
por: Dai, Guixiang, et al.
Publicado: (2021)

Antibody-mediated cell depletion therapies in multiple sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
por: Florou, Despoina, et al.
Publicado: (2020)

Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
por: Roach, Charles A., et al.
Publicado: (2021)

Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy
por: Heming, Michael, et al.
Publicado: (2023)

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
por: de Sèze, Jérôme, et al.
Publicado: (2023)

The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
por: Hauser, Stephen L., et al.
Publicado: (2023)

Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis
por: Simon, Micha, et al.
Publicado: (2018)

Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis()
por: Novak, Frederik, et al.
Publicado: (2021)

Frequency of Regulatory T Cells is Not Affected by Transient B Cell Depletion Using Anti-CD20 Antibodies in Rheumatoid Arthritis
por: Feuchtenberger, Martin, et al.
Publicado: (2008)

Surface Levels of CD20 Determine Anti-CD20 Antibodies Mediated Cell Death In Vitro
por: Singh, Vijay, et al.
Publicado: (2014)

Anti-CD47 antibody eliminates bone tumors in rats
por: Fang, Shiqiang, et al.
Publicado: (2019)

T cells as the hoped-for savior for SARS-CoV-2 vaccination during CD20-depleting antibody therapy?: Commentary for: “Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.”
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Anti-SARS-CoV-2 humoral and cellular responses in multiple sclerosis patients treated with anti-CD20 monoclonal antibodies
por: Nicolas, Philippe, et al.
Publicado: (2022)

Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
por: Margoni, Monica, et al.
Publicado: (2021)

The effect of B-cell depletion with an anti-CD20 antibody on the immunoglobulin heavy-chain repertoire in a patient with rheumatoid arthritis
por: Rouzière, A-S, et al.
Publicado: (2005)

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
por: Spencer, Collin M., et al.
Publicado: (2015)

Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders
por: Lehmann-Horn, Klaus, et al.
Publicado: (2011)

COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases
por: Baker, D., et al.
Publicado: (2020)

An Agonistic Anti-CD137 Antibody Disrupts Lymphoid Follicle Structure and T-Cell-Dependent Antibody Responses
por: Hong, Jun P., et al.
Publicado: (2020)

An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis: Immunotherapy with rituximab, ocrelizumab, and ofatumumab
por: Ovchinnikov, Arkady, et al.
Publicado: (2022)

The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: A network meta-analysis
por: Asha, Mohammad Z.I., et al.
Publicado: (2021)

Efficacy of Accelerated Vaccination against Hbv to Achieve Antibody formation in Multiple Sclerosis Patients Receiving Anti-Cd20 Therapy
por: Koc, Emine Rabia, et al.
Publicado: (2023)

A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
por: Eisenberg, R, et al.
Publicado: (2003)

Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series
por: Fluge, Øystein, et al.
Publicado: (2009)

COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
por: Meca-Lallana, Virginia, et al.
Publicado: (2020)

Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2021)

Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response
por: Singh, Vijay, et al.
Publicado: (2015)

SARS-CoV-2 vaccination in multiple sclerosis: A clearer picture for the time point during CD20 depleting therapy
por: Schulte, Eva C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q93vis6tbcjoqc38cab824bbea